Menu
Home
Forums
New posts
Search forums
What's new
Featured content
New posts
New media
New media comments
New resources
Latest activity
Media
New media
New comments
Search media
Resources
Latest reviews
Search resources
Misc
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Install the app
Install
Home
Forums
Labrish
Nyuuz
South Africa approves Lenacapavir for HIV prevention
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
[QUOTE="Munyaradzi Mafaro, post: 66391, member: 636"] South Africa approved a twice-yearly injectable medication to prevent HIV-1 transmission, becoming the first African nation to authorize the treatment. The regulatory authority cleared Lenacapavir 464mg solution for use on Monday, Oct. 21, marking a significant development for a country with high infection rates. The medication is administered under the skin every 6 months and is indicated for adults and adolescents weighing at least 35 kilograms. Authorities recommend combining the injections with safer sexual practices for maximum protection. The formula received approval from American regulators and European health agencies under different commercial names before South African clearance. Chief executive Boitumelo Semete-Makokotlela described the authorization as transformative for public health efforts. The antiviral represents the most effective prevention method available for blocking HIV-1 infection when used as pre-exposure prophylaxis. [/QUOTE]
Insert quotes…
Name
Post reply
Home
Forums
Labrish
Nyuuz
South Africa approves Lenacapavir for HIV prevention
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top